Skip to Content

Clinical Trials Search Results

Showing 1-10 of 36

Sorted By:

  • A081105

    Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

  • ACCRU RU011201I

    A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer.

  • Alliance A011202

    A randomized phase iii trial evaluating the role of axillary lymph node dissection in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy.

  • Alliance A031201

    Phrase III trial of Enzalutamide versus Enzalutamide, Abiraterone, and Prednisone for Castration Resistant Metastatic Prostate Cancer

  • Alliance A151216

    Genetic Testing For Patients with Resectable or Resected Lung Cancer

  • Alliance Z11102

    Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast cancer (MIBC)

  • BMS 143

    An Expanded Access Program for Elotuzumab in Combination with Lenalidomide plus Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

  • CALGB 50904

    A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib, and Bendamustine in Patients with Untreated Follicular Lymphoma

  • CALGB 80702

    A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

  • CTSU E1A11

    Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Page of 4, showing trials 1-10 of 36

Also in this Section